Several ultrasensitive cell-free tau SAAs have been developed to preferentially detect tau aggregates in the post-mortem brain tissues and CSF of patients with PiD, PSP, CBD and AD [25, 94–96]. This evidence concerns the gene MAPT and red-green color blindness.